ArticleCase reports in ophthalmology
Improvement in Dry Age-Related Macular Degeneration with Photobiomodulation.
Article in Case reports in ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Retinal Autophagy for Sustaining Retinal Integrity as a Proof of Concept for Age-Related Macular Degeneration.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This case report describes a finding of dramatic improvement in drusen volume and visual acuity in a 73-year-old patient diagnosed with dry age-related macular degeneration (AMD) undergoing daily home photobiomodulation alongside AREDS-2 supplements. Case Presentation: This is a retrospective review of a case presentation from 2023 to 2024. After 8 months of continuous home photobiomodulation, the patient's visual acuity improved from 20/30 to 20/20 in the left eye while the right eye stabilized at 20/25. The outer retina was preserved without signs of geographic atrophy, with a robust reduction in the total number and volume of drusen in both eyes, left greater than right, as shown with optical coherence tomography macular cross-sectional scans. Conclusions: These findings support that photobiomodulation has the potential to improve the management of dry AMD and the overall quality of life, consistent with phase III clinical trials. Future studies are warranted to further establish optimized protocols for broader clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.